JP2023507797A5 - - Google Patents

Info

Publication number
JP2023507797A5
JP2023507797A5 JP2022538218A JP2022538218A JP2023507797A5 JP 2023507797 A5 JP2023507797 A5 JP 2023507797A5 JP 2022538218 A JP2022538218 A JP 2022538218A JP 2022538218 A JP2022538218 A JP 2022538218A JP 2023507797 A5 JP2023507797 A5 JP 2023507797A5
Authority
JP
Japan
Prior art keywords
cancer
unsubstituted
substituted
product according
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065415 external-priority patent/WO2021127047A1/en
Publication of JP2023507797A publication Critical patent/JP2023507797A/ja
Publication of JP2023507797A5 publication Critical patent/JP2023507797A5/ja
Pending legal-status Critical Current

Links

JP2022538218A 2019-12-20 2020-12-16 組み合わせ Pending JP2023507797A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962952020P 2019-12-20 2019-12-20
US62/952,020 2019-12-20
US202063009788P 2020-04-14 2020-04-14
US63/009,788 2020-04-14
PCT/US2020/065415 WO2021127047A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (2)

Publication Number Publication Date
JP2023507797A JP2023507797A (ja) 2023-02-27
JP2023507797A5 true JP2023507797A5 (enExample) 2023-12-25

Family

ID=76478122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538218A Pending JP2023507797A (ja) 2019-12-20 2020-12-16 組み合わせ

Country Status (12)

Country Link
US (1) US20230087941A1 (enExample)
EP (1) EP4069240A4 (enExample)
JP (1) JP2023507797A (enExample)
KR (1) KR20220119419A (enExample)
CN (1) CN115038450A (enExample)
AU (1) AU2020407573A1 (enExample)
BR (1) BR112022012280A2 (enExample)
CA (1) CA3165479A1 (enExample)
IL (1) IL294078A (enExample)
MX (1) MX2022007628A (enExample)
TW (1) TW202135809A (enExample)
WO (1) WO2021127047A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566612A3 (en) 2018-03-09 2025-08-20 Recurium IP Holdings, LLC Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
WO2022011391A1 (en) 2020-07-09 2022-01-13 Recurium Ip Holdings, Llc Salts and forms of a wee1 inhibitor
WO2023280180A1 (zh) * 2021-07-05 2023-01-12 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
TW202340196A (zh) * 2021-12-31 2023-10-16 大陸商正大天晴藥業集團股份有限公司 含有雜環的化合物及其應用
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
AU2010247397B2 (en) * 2009-05-15 2012-07-12 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
SG11201607339VA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP4566612A3 (en) * 2018-03-09 2025-08-20 Recurium IP Holdings, LLC Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Similar Documents

Publication Publication Date Title
JP2023507797A5 (enExample)
JP2023508325A5 (enExample)
JP2023508327A5 (enExample)
Ditsch et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2020
JP2023508328A5 (enExample)
Lewis-Wambi et al. Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells
Roche et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial
JP2023508332A5 (enExample)
Gien et al. Brain metastases from endometrial carcinoma: a retrospective study
JP2019529581A5 (enExample)
JP2023526283A5 (enExample)
Schmid et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6
Hutcherson et al. Neurogenic sarcoma of the head and neck
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
JP2018520182A (ja) 乳房障害を処置するための経乳頭方法及び組成物
KR20240073856A (ko) 스피로노락톤 및 아실풀벤의 조합을 이용한 암의 치료
Omlie et al. Acinic cell carcinoma of minor salivary glands: a clinicopathologic study of 21 cases
Liu et al. Pathology of soft-tissue tumors
Baum Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial
ES3030540T3 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
JP2023507799A5 (enExample)
Ellis et al. Estrogen and progesterone receptors in melanocytic lesions: Occurrence in patients with dysplastic nevus syndrome
RU2006123939A (ru) Лечение остеопороза, связанного с терапией ингибиторами ароматазы
Lo et al. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy?
Levy et al. Rhabdomyosarcoma and other soft-tissue sarcomas